Moleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: PR Newswire
HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Dr. Martin Tallman, Chief of Leukemia for Memorial Sloan Kettering Cancer Center has joined the Company's Science Advisory Board (SAB). "The emergence of Annamycin as an important next generation anthracycline for the treatment of relapsed or refractory acute myeloid leukemia is now being recognized at the highest levels of leukemia research," commented Walter Klemp, Moleculin's Chairman and CEO. "We are honored to have Dr. Martin Tallman join the other distinguished members of our SAB." Dr. Martin Tallman added: "There continues to be a significant unmet need for effective second-line induction therapies in AML. Annamycin's apparent lack of cardiotoxicity and demonstrated ability to avoid multi-drug resistance mechanisms make it a promis
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team [Yahoo! Finance]Yahoo! Finance
- Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamAccesswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) [Yahoo! Finance]Yahoo! Finance
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)PR Newswire
MBRX
Analyst Actions
- 3/26/24 - Maxim Group
MBRX
Sec Filings
- 4/25/24 - Form 8-K
- 4/18/24 - Form 8-K
- 4/10/24 - Form 8-K
- MBRX's page on the SEC website